In a major development for Alzheimer’s research, the U.S. POINTER study confirms that lifestyle interventions—when combined with targeted therapeutics—hold the key to slowing cognitive decline. Released at the Alzheimer’s Association International Conference and published in JAMA, the study signals a shift toward precision prevention, a personalized approach to brain health.
The Shift Toward Personalized Alzheimer’s Care
“This is our cancer and heart disease moment for Alzheimer’s,” said Dr. Howard Fillit of the Alzheimer’s Drug Discovery Foundation (ADDF). “Drugs and lifestyle changes alone aren’t enough—it’s time we combine them.”
The study supports ADDF’s vision: targeting individual risk factors—including genetics—with a blend of therapeutics and behavioral strategies.
Key Findings from the U.S. POINTER Study
-
Structured, high-intensity lifestyle changes—diet, exercise, cognitive stimulation—improved cognitive health.
-
Benefits were seen regardless of APOE4 genetic risk, showing broad applicability.
-
Results validated Dr. Miia Kivipelto’s FINGER trial findings, now across a more diverse U.S. population.
What Comes Next?
ADDF is now funding next-generation clinical trials, including the MET-FINGER study, that aim to integrate drugs with personalized prevention plans—redefining how Alzheimer’s is managed.
